Apimeds Pharmaceuticals Declares Material Breach in Merger Deal with Inscobee

Key Facts

Apimeds Pharmaceuticals US Inc. (APUS) has officially declared a material breach of its merger agreement by Inscobee Inc. and its subsidiary, Apimeds Inc. In response to the alleged violation, APUS is preparing to file an emergency legal action in the Delaware Court of Chancery to safeguard its contractual rights and interests. The conflict intensified following Inscobee’s filing of Amendment No. 2 to Schedule 13D with the U.S. Securities and Exchange Commission (SEC). APUS contends that this filing and subsequent actions by Inscobee constitute a direct breach of the established merger terms. This legal escalation introduces significant uncertainty regarding the completion of the merger, likely leading to increased stock volatility for the involved parties. Investors are closely monitoring the situation as potential litigation costs and deal delays could negatively impact the financial standing of both entities.